NEW YORK, Sept. 24, 2025—Millions of people at risk of HIV in low- and middle-income countries will soon gain access to a new HIV prevention tool: a low-cost, generic version of lenacapavir, the first twice-yearly injectable pre-exposure prophylaxis (PrEP). The Bill & Melinda Gates Foundation announced a partnership with Indian pharmaceutical manufacturer Hetero Labs to produce gen... https://healthcare360magazine.com/lenacapavir-hiv-tool/